nociceptin/orphanin peptide receptor (NOP) agonist / Grunenthal - LARVOL DELTA

First participants enrolled in Clinical Trial with Nociceptin/Orphanin peptide receptor (NOP) agonist (PRNewswire) - "Today, Grünenthal announced that the first participants have been enrolled in a randomised, placebo- and active-controlled clinical trial for its peripherally restricted Nociceptin/Orphanin FQ peptide receptor (NOP) agonist....The results of the trial are expected to be available in early 2022....In addition, Grünenthal intends to start a Phase IIa trial to evaluate the compound's efficacy in patients with painful diabetic peripheral neuropathy in 2022....In addition, Grünenthal intends to enrol the first patients with painful osteoarthritis of the knee in a Phase III clinical trial to investigate the efficacy, safety and tolerability of Resiniferatoxin by Q1 2022."

Clinical data • Enrollment status • New P2a trial • CNS Disorders • Diabetic Neuropathy • Neuralgia • Osteoarthritis • Peripheral Neuropathic Pain

Peripheral NOP agonist addressing chronic peripheral neuropathic pain enters clinical development (PRNewswire) - "Grünenthal announced today that the first participants have been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist, an oral investigational medicine with a unique mechanism of action for the treatment of chronic peripheral neuropathic pain...The results of the study are expected to be available in 2021."

Enrollment status • P1 data • CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain